Locally Delivered Minocycline in Advanced Periodontitis
Status:
Completed
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
Local drug delivery provides higher concentrations in the availability of the drug at the
specific infected sites with the advantage of sustained release. Periocline is a long acting
, sustained release local drug delivery system consisting of 2% minocycline hydrochloride in
an ointment containing microcapsule type particles. Periocline contains 20mg of minocycline
in 0.5 gm of gel in a disposable polypropylene applicator (2% minocycline HCl).
Research has yielded promising results with the local application of minocycline in the
treatment of periodontal disease, compared with other non-surgical therapies. However, there
is scarcity of reports on the use of local delivery agents with respect to new range of
putative pathogens in advanced periodontitis, wherein the tissue invasive anaerobic organisms
are present and possibly compromised host response, hence resulting in an exaggerated
breakdown of periodontal tissues at the affected sites. The effect of Minocycline on new
putative pathogens, such as Filifactor alocis and oral phylotypes of phyla Synergistetes and
TM7 (referred to hereafter as oral Synergistetes and oral TM7s), has not been investigated
yet.
Hence, the aim of the present study is to evaluate the efficacy of a local delivery agent
containing minocycline (Periocline, Sunstar, Japan) as an adjunct to SRP in the treatment of
deep periodontal pockets around teeth in advanced periodontitis and the antimicrobial effect
on the red complex and the new putative pathogens.